

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience

RRID:AB_469584

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 25-0081-82, RRID:AB_469584

Antibody Information

URL: http://antibodyregistry.org/AB_469584

Proper Citation: Thermo Fisher Scientific Cat# 25-0081-82, RRID:AB_469584

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow
Consolidation on 1/2020: AB_469584, AB_10113390

Antibody Name: CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_469584

Vendor: Thermo Fisher Scientific

Catalog Number: 25-0081-82

Record Creation Time: 20251213T073809+0000

Record Last Update: 20260903T215520+0000

Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 63 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bajbouj K, et al. (2026) Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors. Cancer immunology research, 14(4), 559.

Palmer P, et al. (2026) A computational method to design broad-spectrum T cell-inducing vaccines applied to Betacoronaviruses. Cell reports methods, 101508.

Murakami R, et al. (2026) Foxp3 and BATF cooperatively direct cis-regulatory programs and gene expression for effector Treg cell differentiation. Immunity, 59(5), 1253.

Luo Y, et al. (2026) CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. Clinical science (London, England : 1979), 140(1).

Laubretton D, et al. (2026) Transient tumor exposure induces persistent functional defects in memory CD8+ T cells. iScience, 29(5), 115556.

Westfall S, et al. (2025) A type 1 immune-stromal cell network mediates disease tolerance against intestinal infection. Cell, 188(12), 3135.

Marchand T, et al. (2025) Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury. eLife, 13.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. Cancer discovery, 15(4), 838.

Longo J, et al. (2025) Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control. Cell metabolism, 37(9), 1890.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Léger J, et al. (2025) The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors. Immunity, 58(11), 2685.

Baptista AP, et al. (2025) TLR ligand sensing by lymph node FRCs directs intranodal lymphocyte accumulation to promote immune responses. *iScience*, 28(11), 113734.

Yagi M, et al. (2025) Bivalent chromatin instructs lineage specification during hematopoiesis. *Cell*, 188(16), 4314.

Wang F, et al. (2025) An age-related decrease in leptin contributes to CD8⁺ T cell aging in the tumor microenvironment. *Cell reports. Medicine*, 6(9), 102310.

Rennen S, et al. (2025) Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways. *Cell reports*, 44(8), 116150.

Cai W, et al. (2025) The gut microbiota promotes pain in fibromyalgia. *Neuron*, 113(13), 2161.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. *Cell reports. Medicine*, 5(5), 101567.

Fay M, et al. (2024) TGF- β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. *iScience*, 27(8), 110520.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2⁺ tumor cells drive CD8⁺ T cell senescence and cervical cancer recurrence. *Cell reports. Medicine*, 5(5), 101550.